Actinomycin

Jump to: navigation, search
220px
Actinomycin
Systematic (IUPAC) name
(Dactinomycin )
Identifiers
CAS number 50-76-0
ATC code L01DA01
PubChem 2019
DrugBank APRD00124
Chemical data
Formula C62H86N12O16 
Mol. mass 1255.42 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding 5%
Metabolism  ?
Half life 36 hours
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

WikiDoc Resources for Actinomycin

Articles

Most recent articles on Actinomycin

Most cited articles on Actinomycin

Review articles on Actinomycin

Articles on Actinomycin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Actinomycin

Images of Actinomycin

Photos of Actinomycin

Podcasts & MP3s on Actinomycin

Videos on Actinomycin

Evidence Based Medicine

Cochrane Collaboration on Actinomycin

Bandolier on Actinomycin

TRIP on Actinomycin

Clinical Trials

Ongoing Trials on Actinomycin at Clinical Trials.gov

Trial results on Actinomycin

Clinical Trials on Actinomycin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Actinomycin

NICE Guidance on Actinomycin

NHS PRODIGY Guidance

FDA on Actinomycin

CDC on Actinomycin

Books

Books on Actinomycin

News

Actinomycin in the news

Be alerted to news on Actinomycin

News trends on Actinomycin

Commentary

Blogs on Actinomycin

Definitions

Definitions of Actinomycin

Patient Resources / Community

Patient resources on Actinomycin

Discussion groups on Actinomycin

Patient Handouts on Actinomycin

Directions to Hospitals Treating Actinomycin

Risk calculators and risk factors for Actinomycin

Healthcare Provider Resources

Symptoms of Actinomycin

Causes & Risk Factors for Actinomycin

Diagnostic studies for Actinomycin

Treatment of Actinomycin

Continuing Medical Education (CME)

CME Programs on Actinomycin

International

Actinomycin en Espanol

Actinomycin en Francais

Business

Actinomycin in the Marketplace

Patents on Actinomycin

Experimental / Informatics

List of terms related to Actinomycin


Actinomycin is any of a class of polypeptide antibiotics isolated from soil bacteria of the genus Streptomyces.

Mechanism

Actinomycin-D is primarily used as an investigative tool in cell biology to inhibit transcription. It does this by binding DNA at the transcription initiation complex and preventing elongation by RNA polymerase.[1]

As it can bind DNA duplexes, it can also interfere with DNA replication, although other chemicals such as hydroxyurea are better suited for use in the laboratory as inhibitors of DNA synthesis.

Clinical use

As chemotherapy

Actinomycin-D is marketed under the trade name Dactinomycin. Actinomycin-D is one of the older chemotherapy drugs which has been used in therapy for many years.

It is a clear, yellow liquid which is administered intravenously and most commonly used in treatment of a variety of cancers, including:

As an antibiotic

It was the first antibiotic shown to have anti-cancer activity, but is not normally used as such, as it is highly toxic, causing damage to genetic material.

It was the first antibiotic ever isolated by Selman Waksman.

Research use

Actinomycin-D and its fluorescent derivative, 7-amino-actinomycin D, are used as stains in microscopy and flow cytometry applications. The affinity of these stains compounds for GC-rich regions of DNA strands makes them excellent markers for DNA.

7-amino-actinomycin D (7aad) is used as a DNA stain .7aad binds to single stranded DNA. Therefore it is a useful tool in determining apoptosis and distinguishing between dead cells and live ones. (Source)

References

  1. Sobell H (1985). "Actinomycin and DNA transcription". Proc Natl Acad Sci U S A. 82 (16): 5328–31. PMID 2410919. 
  2. Turan T, Karacay O, Tulunay G, Boran N, Koc S, Bozok S, Kose M. "Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia". Int J Gynecol Cancer. 16 (3): 1432–8. PMID 16803542. 
  3. Abd El-Aal H, Habib E, Mishrif M (2005). "Wilms' Tumor: The Experience of the Pediatric Unit of Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK)". J Egypt Natl Canc Inst. 17 (4): 308–11. PMID 17102824. 
  4. Khatua S, Nair C, Ghosh K (2004). "Immune-mediated thrombocytopenia following dactinomycin therapy in a child with alveolar rhabdomyosarcoma: the unresolved issues". J Pediatr Hematol Oncol. 26 (11): 777–9. PMID 15543019. 

External links

de:Actinomycineko:악티노마이신

Linked-in.jpg